Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 7:32 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1591
Shown on this page
12
Current sort
Recently updated
Campus scope
Ohio State University Wexner Medical Center, Columbus, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Ohio State University Wexner Medical Center, Columbus, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 649–660 of 1,591 matching trials with a site at Ohio State University Wexner Medical Center, Columbus, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222
Status at this site: Recruiting
Conditions
Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions
TUB-030
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more
Active, not recruiting Phase 1 Interventional

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

NCT01861314
Site status not listed — check the official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Bortezomib, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

NCT05520567
Site status not listed — check the official record
Conditions
Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
Interventions
Gilteritinib, Venetoclax, Azacitidine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 12 more
Recruiting No phase listed Observational

Serum Inflammatory Protein Concentration During Dental Treatment

NCT07468929
Status at this site: Recruiting
Conditions
Periodontal Disease, Periodontal Surgery
Interventions
Blood samples for inflammatory markers, periodontal surgery, Periodontal maintenance, Non-surgical deep cleaning
Other · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting Phase 3 Interventional

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

NCT05438212
Site status not listed — check the official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
208
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more
Conditions
Opioid Use Disorder, Dual Diagnosis, Housing Problems, Mental Disorder in Adolescence, Risk Behavior, Homelessness
Interventions
Motivational Interviewing/Community Reinforcement Approach (MI/CRA), Strengths-Based Outreach and Advocacy (SBOA ), Services as Usual (SAU)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 24 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Columbus, Ohio
Conditions
Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Pemigatinib, Survey Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Recruiting Not applicable Interventional

A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation

NCT05547698
Status at this site: Recruiting
Conditions
Lung Transplant
Interventions
Off-pump lung transplantation, Venoarterial ECMO lung transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Louisville, Kentucky + 6 more
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
Status at this site: Recruiting
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Interventions
Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
230
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more
Conditions
Back Pain
Interventions
Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine, Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Jacksonville, Florida • Baltimore, Maryland • Rochester, Minnesota + 2 more

About this Ohio State University Wexner Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.